# Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer

> **NCT00524121** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 22 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **OTHER:** immunohistochemistry staining method
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00524121
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2010-05
- **Final completion:** 2011-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00524121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00524121, "Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00524121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*